摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4'-oxo-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxylate | 1051383-43-7

中文名称
——
中文别名
——
英文名称
tert-butyl 4'-oxo-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxylate
英文别名
1-Boc-4'-oxo-3',4'-dihydrospiro[piperidine-4,2'-pyrano[3,2-B]pyridine];tert-butyl 4-oxospiro[3H-pyrano[3,2-b]pyridine-2,4'-piperidine]-1'-carboxylate
tert-butyl 4'-oxo-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxylate化学式
CAS
1051383-43-7
化学式
C17H22N2O4
mdl
——
分子量
318.373
InChiKey
FAAPLOBZDDRWTF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    68.7
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    tert-butyl 4'-oxo-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxylate 在 sodium tetrahydroborate 作用下, 以 乙醇 为溶剂, 以99%的产率得到
    参考文献:
    名称:
    Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors
    摘要:
    Spirocyclic secondary amine-derived trisubstituted ureas were identified as highly potent, bioavailable and selective soluble epoxide hydrolase (sEH) inhibitors. Despite good oral exposure and excellent ex vivo target engagement in blood, one such compound, rac-1a, failed to lower blood pressure acutely in spontaneously hypertensive rats (SHRs). This study posed the question as to whether sEH inhibition provides a robust mechanism leading to a significant antihypertensive effect. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.05.036
  • 作为产物:
    描述:
    1-(3-羟基吡啶-2-基)乙酮N-叔丁氧羰基-4-哌啶酮四氢吡咯 作用下, 以 methnolanol 为溶剂, 反应 24.0h, 以31%的产率得到tert-butyl 4'-oxo-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxylate
    参考文献:
    名称:
    TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE
    摘要:
    本发明涉及新型三环螺环衍生物,包括该三环螺环衍生物的药物组合物,以及利用这些化合物治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、消化系统紊乱、神经系统紊乱、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖异常。
    公开号:
    US20110166124A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2123652A1
    公开(公告)日:2009-11-25
    The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein each symbol is as in the specification, or a salt thereof.
    本发明提供了一种具有ACC抑制作用的化合物,该化合物用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉减少症、癌症等疾病,并具有优异的疗效。 本发明提供了一种由公式(I)表示的化合物: 其中每个符号如说明书所述,或其盐。
  • [EN] HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE CHROMÈNE HÉTÉROCYCLIQUE-PIPÉRIDINE SPIROCYCLIQUE UTILES COMME MODULATEURS DES CANAUX IONIQUES
    申请人:VERTEX PHARMA
    公开号:WO2011140425A1
    公开(公告)日:2011-11-10
    The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    本发明涉及杂环色烯-螺环哌啶酰胺,用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药用可接受组合物,以及使用这些组合物治疗各种疾病的方法。
  • [EN] BENZOXAZINES AS MODULATORS OF ION CHANNELS<br/>[FR] BENZOXAZINES COMME MODULATEURS DES CANAUX IONIQUES
    申请人:VERTEX PHARMA
    公开号:WO2013067248A1
    公开(公告)日:2013-05-10
    The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    本发明涉及可用作离子通道抑制剂的苯并噁嗪。本发明还提供了包含本发明化合物的药用可接受组合物,以及使用这些组合物治疗各种疾病的方法。
  • HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
    申请人:Hadida-Ruah Sara Sabina
    公开号:US20110306607A1
    公开(公告)日:2011-12-15
    The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    本发明涉及杂环色烯-螺环哌啶酰胺类化合物,其可用作离子通道抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物,并提供了使用这些组合物治疗各种疾病的方法。
  • Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
    申请人:HADIDA-RUAH Sara Sabina
    公开号:US20140171427A1
    公开(公告)日:2014-06-19
    The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    本发明涉及杂环色烯-螺环哌啶酰胺,其可用作离子通道抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病的方法。
查看更多

同类化合物

龙胆胺 龙胆定碱 西藏龙胆碱 萤光红BK 苯酰胺,N-(1,5,7,8-四氢-4-羰基-4H-吡喃并[4,3-b]吡啶-3-基)- 秦艽碱丙 秦艽甲素 盐酸伊立替康杂质20 溶剂红197 吡喃联氮基[2,1-c][1,4]苯并噁嗪,1,2,3,4,4a,5-六氢-(9CI) 伊立替康杂质29 α.-D-核-七吡喃糖苷-6-酮糖,甲基3,7-二脱氧-2-O-甲基-4-O-(苯基甲基)- N-(3,4-二氢-2H-吡喃并[3,2-b]吡啶-4-基)-n-甲基甘氨酸 N-(2-(4-甲氧苯基)乙烯基)-吡咯烷-2,5-二酮 8-碘-3,4-二氢-2H-吡喃并[3,2-c]吡啶 7H-噻喃并[2,3-d]嘧啶 7-溴-2H-吡喃并[3,2-b]吡啶 7-氯-3,4-二氢-2H-吡喃并[2,3-B]吡啶 7-乙基-10-羟基喜树碱中间体 7,8-二氢-6H-硫代吡喃并[3,2-d]嘧啶-2,4-二醇 7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-胺 7,8-二氢-2-(甲硫基)-3H-噻喃并[3,2-d]嘧啶-4(6H)-酮 6H-噻喃并[3,2-d]嘧啶 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-甲醛 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶 6-甲基-3,4-二氢吡喃并[4,3-d]吡啶-1-酮 6-溴-2H-吡喃并[2,3-b]吡啶-4(3H)-酮 6-溴-2-苯基-2H-吡喃并[2,3-b]吡啶 6-溴-2-(4-甲基苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-溴-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(4-氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,4-二氢-2H-吡喃[2,3-b]吡啶 6,8-二碘-3,4-二氢-2H-吡喃[3,2-b]吡啶 5H-噻喃并[2,3-d]嘧啶 5-氧杂-10-氮杂三环[6.2.1.04,9]十一碳-1,3,7,9-四烯 5,8-二氢-6H-吡喃并[3,4-b]吡啶 4H-吡喃并[2,3-b]吡啶-4-酮,6-氯-2,3-二氢-2-甲基-,(R)- 4H-吡喃并[2,3-b]吡啶-4-酮 4-羟甲基-3,4-二氢-2H-吡喃[3,2-B]吡啶-4-醇 4-甲基-7-吗啉基-2H-吡喃并[2,3-b]吡啶-2-酮 4-乙基-7,8-二氢-4-羟基-1H-吡喃并[3,4-f]吲嗪-3,6,10(4H)-三酮 4,4',5'-三甲基氮杂补骨脂素 4'-乙基-7',8'-二氢-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3',10'(4′H)-二酮-d5 4'-乙基-7',8'-二氢-4'-羟基-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3′,10′(4′H)-二酮-d5 3-异噻唑甲酰胺,N-(4-氯-7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-基)- 3-(二烯丙基氨基)-7-氧代-7H-苯并吡喃并[3',2':3,4]吡啶并[1,2-a]苯并咪唑-6-甲腈 3-(4-羟苯在)-4H-吡喃[2,3-B]吡啶-4-酮 3,4-二氢-4-亚甲基-(9ci)-2H-吡喃并[3,2-b]吡啶 3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-羧酸